Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price hoisted by Piper Sandler from $210.00 to $215.00 in a report released on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.
A number of other equities analysts have also recently weighed in on NBIX. Truist Financial increased their price target on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Needham & Company LLC restated a “buy” rating and issued a $204.00 price objective on shares of Neurocrine Biosciences in a report on Friday, October 16th. Morgan Stanley boosted their price objective on shares of Neurocrine Biosciences from $182.00 to $183.00 and gave the company an “equal weight” rating in a report on Friday, September 11th. Guggenheim began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, October 6th. They issued a “buy” rating and a $207.00 target price on the stock. Finally, Stifel Nicolaus increased their target price on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $202.32.
Read Our Latest Stock Report on Neurocrine Biosciences
Neurocrine Biosciences Stock Performance
Shares of Neurocrine Biosciences stock opened at $159.76 on Tuesday. The firm has a market capitalization of $16.17 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 0.74 and a beta of 0.36. Neurocrine Biosciences has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The stock has a 50 day moving average of $147.04 and a 200 day moving average of $147.90.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the firm earned $2.04 earnings per share. The firm’s quarterly revenue was up 41.3% compared to the same quarter last year. Analysts forecast that Neurocrine Biosciences will post 7.66 EPS for the current year.
Insider Buying and Selling at Neurocrine Biosciences
In other Neurocrine Biosciences news, CFO Matt Abernethy sold 2,311 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the transaction, the chief financial officer directly owned 42,808 shares in the company, valued at $6,729,417.60. This represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,200 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $166.37, for a total value of $1,197,864.00. Following the transaction, the director owned 10,386 shares of the company’s stock, valued at approximately $1,727,918.82. This represents a 40.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,137 shares of company stock valued at $2,829,332 over the last quarter. 4.60% of the stock is owned by company insiders.
Hedge Funds Weigh In On Neurocrine Biosciences
Hedge funds have recently bought and sold shares of the company. Fifth Third Bancorp lifted its holdings in Neurocrine Biosciences by 6.6% during the 3rd quarter. Fifth Third Bancorp now owns 32,218 shares of the company’s stock worth $4,570,000 after buying an additional 2,001 shares during the last quarter. New Mexico Educational Retirement Board increased its holdings in shares of Neurocrine Biosciences by 6.6% in the 3rd quarter. New Mexico Educational Retirement Board now owns 21,000 shares of the company’s stock valued at $2,979,000 after acquiring an additional 1,300 shares during the last quarter. Maryland State Retirement & Pension System increased its holdings in shares of Neurocrine Biosciences by 2.2% in the 3rd quarter. Maryland State Retirement & Pension System now owns 5,714 shares of the company’s stock valued at $810,000 after acquiring an additional 123 shares during the last quarter. Jacobi Capital Management LLC purchased a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at about $42,000. Finally, Philadelphia Trust Co. raised its position in shares of Neurocrine Biosciences by 0.4% during the 3rd quarter. Philadelphia Trust Co. now owns 30,270 shares of the company’s stock worth $4,293,000 after acquiring an additional 135 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.
More Neurocrine Biosciences News
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
- Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
- Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
- Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
- Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.
Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.
Read More
- Five stocks we like better than Neurocrine Biosciences
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
